GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease

NCT06546384 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing whether a medication called a GLP-1 receptor agonist reduces alcohol consumption and improves liver health in adults with obesity and fatty liver disease.

Status Not yet recruiting Approved but enrollment has not started.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 64 people Planned (estimated).

Who can join Ages 18–80 · all sexes

Timeline Started 2026-05 · est. completion 2027-04

Where 1 site · Switzerland

What this study is testing ClinicalTrials.gov NCT06546384 ↗

Description as written by the study sponsor.

There is evidence that alcoholic beverage consumption significantly interacts with food energy intake. Furthermore, there is accumulating evidence showing independent, combined, and modifying effects of alcohol and metabolic factors on the onset and progression of chronic liver disease. Preclinical and clinical data have showed that GLP-1 RA can decrease alcohol consumption, particularly in obese patients. Moreover there is evidence that semaglutide can improve the liver sinusoidal milieu in pre-clinical models of cirrhosis. In this study, the investigators aim to assess if patients treated with semaglutide and receiving counselling will achieve a significantly higher alcohol abstinence compared to patients only receiving counselling.

Treatments tested

Semaglutide Drug

Treatment with semaglutide, following standard clinical practice as per below schedule: Week 1-4: Injected dose of 0,25 mg i.d. Week 5-8: Injected dose of 0,5 mg i.d. Week 9-12: Injected dose of 1,0 mg i.d. Week 13-16: Injected dose of 1,7 mg i.d. After week 16: Injected dose of 2,4 mg i.d.
Weight reduction recommendations (nutritional and exercise) Behavioral

Participants will receive nutritional and exercise recommendations and 2 telephone consultations

Main thing measured	Proportion of patients achieving total alcohol abstinence (measured by negative PEth test)
Sponsor	Insel Gruppe AG, University Hospital Bern
Conditions studied	Adiposity, Fatty Liver, Alcohol Use Disorder
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06546384 ↗